334 clinical trials
grid
list
download
- Title Organ Phase Statut Major inclusion criteria Contact
-
The APOLLO Study
A phase III Study comparing Pomalidomide and Dexamethasone with or without Daratumumab in Subjects with Relapsed or Refractory Multiple Myeloma who have received at least one prior line of therapy with both Lenalidomide and a Proteasome Inhibitor
Myeloma
phase
3
Closed
- prior anti-myeloma treatment included both a PI- and lenalidomide-containing regimens
- no previous therapy with Pomalidomide nor CD-38 MoAb - THINK A multinational, open-label, dose escalation Phase I/II study to assess the safety and clinical activity of multiple administrations of NKR-2 in patients with different metastatic tumor types Multiple phase 1/2 Closed relapsed or refractory AML / MDS with R-IPSS ? 2 with failure to prior treatment/ not eligible for standard of care therapy
- TIG-007 Study of EOS884448 alone, and in combination with iberdomide with or without dexamethasone, in participants with relapse or refractory multiple myeloma (TIG-007) Myeloma phase 1/2 Open Progression on last line of treatment, no other therapeutic option
- TiNivo-2 A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination with Nivolumab to Tivozanib Monotherapy in Subjects with Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line has an Immune Checkpoint Inhibitor Kidney phase 3 Closed
- TK-SCR-01 Assessing Frequency of HLA-Genotypes and Tumor Antigen Expression in Subjects with Relapsed/Refractory, Advanced-Stage Solid Tumors that may Qualify for Novel T Cell Receptor Based Therapies Multiple Closed
- TOTAL A phase II study of brentuximab vedotin in patients with relapsed or refractory peripheral T-cell lymphoma treated with gemcitabine followed by brentuximab vedotin maintenance (TOTAL) Non-Hodgkin lymphoma phase 2 Closed CD30 positive Peripheral T-cell Lymphoma/Ann Arbor stage I-IV/at least 1 measurable lesion >=1,5cm
- TOUCH Phase II open-label, multicenter, randomized trial of neoadjuvant palbociclib in combination with hormonal therapy and HER2 blockade versus paclitaxel in combination with HER2 blockade for elderly patients with hormone receptor positive/HER2 positive early breast cancer (IBCSG 55-17 / TOUCH) Breast phase 2 Closed ER+/HER2+. cT1-3. N0-1. >1 cm. Neoadjuvant. Age >65 years old
- TROPION-Breast01 A Phase 3, Open-label, Randomized Study of Dato-DXd Versus Investigator's Choice of Chemotherapy in Participants With Inoperable or Metastatic Hormone Receptor-Positive, HER2-Negative Breast Cancer Who Have Been Treated With One or Two Prior Lines of Systemic Chemotherapy Breast phase 3 Closed
- TROPION-Breast02 A Phase 3, Open-label, Randomised Study of Datopotamab Deruxtecan (Dato-DXd) Versus Investigator's Choice of Chemotherapy in Patients who are not Candidates for PD-1/PD-L1 Inhibitor Therapy in First-line Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer (TROPION-Breast02) Breast phase 3 Open
- TROPION-Breast03 A Phase 3 Open-label, Randomised Study of Datopotamab Deruxtecan (DatoDXd) With or Without Durvalumab Versus Investigator's Choice of Therapy in Patients With Stage I-III Triple-negative Breast Cancer Who Have Residual Invasive Disease in the Breast and/or Axillary Lymph Nodes at Surgical Resection Following Neoadjuvant Systemic Therapy (TROPION-Breast03) Breast phase 3 Open
- TULIP A multi-centre, open-label, randomized clinical trial comparing the efficacy and safety of the antibody-drug conjugate SYD985 to physician's choice in patients with HER2-positive unresectable locally advanced or metastatic breast cancer / TULIP Breast phase 3 Closed HER2 positive/ RECIST 1.1/ After HER2 targeting treatment
- UPSTREAM A pilot study of personalized biomarker-based treatment strategy or immunotherapy in patients with recurrent/metastatic squamous cell carcinoma of the head and neck "UPSTREAM" Bones - soft tissue phase 2 Closed Second line metastatic, biopsy
- VIOLETTE A Phase II, Open Label, randomized, Multi-center Study to Assess the Safety and Efficacy of Agents Targeting DNA Damage Repair in Combination with Olaparib versus Olaparib Monotherapy in the Treatment of Metastatic Triple Negative Breast Cancer Patients Stratified by Alterations in Homologous Recombinant Repair (HRR-Related Genes (including BRCA 1/2) (VIOLETTE) Breast phase 2 Closed Progressive. At least 1 line of athracycline and/or taxane
-
VISION
VISION: An international, prospective, open label, multicenter, randomized Phase 3 study of 177Lu-PSMA-617 in the treatment of patients with progressive PSMA-positive metastatic castration-resistant prostate cancer (mCRPC)
prostate
phase
3
Closed
*Must have received at least one NAAD(enzalutamide or abiraterone).
*1 or 2 prior treatment with taxane
*Progressive disease